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Abstract
Purpose Tadalafil seems to ameliorate insulin resistance
and glucose homeostasis in humans. We have previously
reported that tadalafil targets human skeletal muscle cells
with an insulin (I)-like effect. We aim to evaluate in human
fetal skeletal muscle cells after tadalafil or I: (i) expression
profile of I-regulated genes dedicated to cellular energy
control, glycolitic activity or microtubule formation/vesicle
transport, as GLUT4, PPARγ, HK2, IRS-1, KIF1C, and
KIFAP3; (ii) GLUT4, Flotillin-1, and Caveolin-1 localiza-
tion, all proteins involved in energy-dependent cell traf-
ficking; (iii) activation of I-targeted paths, as IRS-1, PKB/
AKT, mTOR, P70/S6K. Free fatty acids intracellular level
was measured. Sildenafil or a cGMP synthetic analog were
used for comparison; PDE5 and PDE11 gene expression
was evaluated in human fetal skeletal muscle cells.
Methods RTq-PCR, PCR, western blot, free fatty acid
assay commercial kit, and lipid stain non-fluorescent assay
were used.
Results Tadalafil upregulated I-targeted investigated genes
with the same temporal pattern as I (GLUT4, PPARγ, and
IRS-1 at 3 h; HK2, KIF1C, KIFAP3 at 12 h), re-localized
GLUT4 in cell sites positively immune-decorated for
Caveolin-1 and Flotillin-1, suggesting the involvement of
lipid rafts, induced specific residue phosphorylation of IRS-
1/AKT/mTOR complex in association with free fatty acid
de novo synthesis. Sildenafil or GMP analog did not affect
GLUT4 trafficking or free fatty acid levels.
Conclusion In human fetal skeletal muscle cells tadalafil
likely favors energy storage by modulating lipid home-
ostasis via IRS-1-mediated mechanisms, involving activa-
tion of I-targeted genes and intracellular cascade related to
metabolic control. Those data provide some biomolecular
evidences explaining, in part, tadalafil-induced favorable
control of human metabolism shown by clinical studies.
Keywords PDE5i ● Tadalafil ● Insulin ● Skeletal muscle ●
Metabolism
Introduction
Phosphodiesterase type 5 inhibitors (PDE5i), including
avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, varde-
nafil, udenafil, zaprinast, icariin and its synthetic deriva-
tives, benzamidenafil, and dasantafil, have found their
widest clinical application to treat erectile dysfunction (ED),
due to their effective vasodilatory action [1–3].
Tadalafil and sildenafil have been proven not only to be
safe in diabetic men experiencing ED [4–7] but also to
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directly control metabolism regulation, as insulin resistance
(IR) or type 2 diabetes (T2D) that tend to ameliorate after
PDE5 specific inhibition [8–13].
While, at first, indirect effects - mainly based on nitric
oxide (NO) release by endothelial cells - have been invoked
to explain PDE5i-induced control of metabolism [6, 14],
later in vivo and in vitro evidences showed direct actions of
PDE5i onto metabolic processes at muscular level [15–18].
Physical exercise improves general health [19–21] and in
this context, skeletal muscle, accounting for about 85% of
whole-body, plays a key role as insulin (I)-stimulated glu-
cose disposal and metabolic balance [22].
We have previously reported that tadalafil directly targets
human skeletal muscle cells with an I-like effect, activating
part of energy-dedicated cellular machinery [17].
Herein, we aim to further investigate whether tadalafil
can modulate: the expression of some specific genes clas-
sically I-targeted; the intracellular trafficking of glucose
transporter type 4 (GLUT4), the main glucose transporter at
muscular level; part of the intracellular cascade specifically
dedicated to I-driven energy management.
To this purpose, human fetal skeletal muscle cells (Hfsmc) -
a reliable cell system previously assessed [23, 24] - were
analyzed after exposure to tadalafil vs. I for: time-dependent
mRNA expression specific for GLUT4, peroxisome
proliferator-activated receptor gamma (PPARγ), hexokinase 2
(HK2), insulin receptor substrate 1 (IRS-1), kinesin family
member 1 C (KIF1c), and kinesin-associated protein 3
(KIFAP3), all I-responsive genes engaged in different cell
metabolic functions [25–29]; protein localization of GLUT4,
along with Flotillin-1 (FLOT1) and Caveolin-1 (CAV1),
inducible and structural intracellular protein components,
respectively, involved in cell membrane reorganization/vesicle
formation in glucose-dependent trafficking; intracellular acti-
vation of IRS-1, protein kinase B (PKB or AKT), mammalian
target of rapamycin (mTOR), P70/S6 kinase (P70/S6K) and
GSK3β, all paths engaged in I-driven metabolic response;
intracellular free fatty acids (ffa) content. Since tadalfil exhibits
a potent inhibitory activity onto PDE11, its expression was
investigated in Hfsmc in comparison with PDE5.
In order to determine the possible selectivity of tadalfil
effect, some experiments were performed in comparison
with the PDE5i sildenafil or the cGMP analog 8-
Bromoguanosine 3′,5′-cyclic monophosphate sodium salt
(8-br-cGMP).
Materials and methods
Chemicals
Tadalafil powder (100% pure) was provided by ELI Lilly
ICOS Corporation (Indianapolis, USA). Dulbecco
modified eagle medium (DMEM)/Ham’s F-12 medium
(1:1) with and without phenol red, phosphate buffered
saline (PBS) Ca2+/Mg2+ -free, bovine serum albumin
(BSA) fraction V, glutamine, antibiotics, collagenase type
IV, EDTA-trypsin solution, NaOH, Bradford Reagent,
4′,6-Diamidino-2-phenylindole (DAPI), Paraformaldehyde
(PFA), Triton™ X (TX)-100, I, PDE5 inhibitor sildenafil
citrate salt, 8-br-cGMP all reagents for western blot,
polymerase chain reaction (PCR) and gel electrophoresis
of PCR products were from Sigma Aldrich Corp. (St.
Louis, MO, USA). Fetal bovine serum (FBS) was from
HyClone (Logan, UT, USA). 2-mercaptoethanol and
SYBR® Green PCR Master Mix for qPCR were from Life
Technologies, Inc. Laboratories (Grand Island, NY).
Antibodies (Abs) for western blot and immunocytochem-
ical analysis: anti-phospho-Ser-2481-mammalian target of
rapamycin (p-mTORSer2441) (SC-293132M), anti-phos-
pho-Ser-473-protein kinase B 1/2/3 (p-AKT1/2/3Ser473)
(SC-7985), anti-phospho-Tyr-632-Insulin receptor sub-
strate 1 (p-IRSTyr632) (SC-17196), AKT (SC-1618), IRS
(SC-559), FLOT1 (SC-25506), β-ACTIN (SC-47778)
were from Santa Cruz (CA, USA), anti-phospho-Ser-2448-
mTOR (p-mTORSer2448) (2971), anti-phospho-Ser-21/9
Glycogen Synthase Kinase 3-β (p-GSK3-β) (9331), anti-
Glycogen Synthase Kinase 3-β (9315) were from Cell
Signaling (MA, USA), anti-CAV1 (Ab2910), GLUT4
FITC conjugated (Ab65297), and anti-c-Myc (Ab17356)
were from Abcam (Cambridge, UK). FITC-labeled and
Cy3-labeled secondary antibody were from Jackson
Laboratory (Maine, USA). Plastic ware for cell cultures
and disposable filtration units for growth media prepara-
tion were purchased from Corning (Milan, Italy).
Cell cultures
Hfsmc were obtained as previously described [23, 24].
Briefly cells were isolated from 11 fetal skeletal male
muscles (four upper and seven lower limbs) obtained after
voluntary abortion (10–12 weeks of gestation). Legal
abortions were performed in authorized hospital and written
consent was given by the patients for human fetal tissue to
be stored and used for research. The use of human fetal
tissue for research purposes was approved by the Com-
mittee for investigation in humans of the Azienda
Ospedaliero–Universitaria Careggi, Florence, Italy (proto-
col n◦ 6783-04). All samples have been handled in the
same way and maintained in ice-cold PBS until processed
for culture preparation as described elsewhere [30]. Con-
fluent cell cultures were split into a 1:2–1:4 ratio using
EDTA-trypsin solution (0.2–0.5%), and used from 5th to
12th passage (5p–12p). LNCaP clone FGC (ATCC® CRL-
1740™) was purchased from ATCC. Cell cultures in
DMEM/Ham’s F-12 or RPMI-1640 supplemented with 10%
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heat inactivated FBS, 2 mM glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin were maintained in a fully
humidified atmosphere of 95% air and 5% CO2.
RNA Extraction, Reverse Transcription Real-Time
Quantitative PCR and semi-quantitive PCR
For mRNA analysis: 35,000 Hfsmc were seeded in 35-mm
culture dishes and maintained for 24 h in their growth
medium; after 12 h of starvation (medium without serum
and without phenol red), cells were stimulated for 24 h with
tadalafil (0.5 μM) and I (100 nM) for 24 h in serum-free
medium containing 0.1% BSA in serum-free medium with
0.1% BSA, cells in serum-free medium containing 0.1 %
BSA and vehicle were used as control. Total RNA was
extracted from cultured cells using TRIzol® RNA Isolation
Reagents (Ambion™) according to the manufacturer’s
instructions. Single-stranded cDNA was obtained by
reverse transcription of 1 μg of total RNA.
RT-qPCRs were performed using 7500 Real Time Sys-
tem (Applied Biosystems®) with SYBR-green fluorophore;
40 ng of cDNA were used as template and cycling para-
meters were 95°C for 10 min, followed by 40 cycles of 15 s
at 95°C, 1 min at 60°C, 30 s at 95°C, 15 s at 60°C. Fluor-
escence intensities were analyzed using the manufacturer’s
software (7500 Software v2.05) and relative amounts were
obtained using the 2−ΔΔCt method and normalized for the ß-
actin. Data are expressed as fold increase vs. control taken
as 1. Primers for GLUT4: Fw CACCCTCACCACCC
TCTG, Rev CTTTTCCTTCCAAGCCACTG; for β-actin:
Fw CTGAACCCCAAGGCCAAC, Rev AGCCTGGATAG
CAACGTACA; for PPARγ: Fw GCAATCAAAGTGGAG
CCTGC, Rev TCTCCGGAAGAAACCCTTGC; for IRS-1:
Fw TTCGGTACATCCTCGACGGC, Rev TGATGAACA
TCAGGCGCTGT; for KIF1C: Fw ACAACGTGTGTGCA
TCTTTGCC, Rev TCGTACCCGCTCACAGTAGA; for
HK2: Fw ATGGAGAAAGGGCTTGGAGC, Rev CCAAA
GCACACGGAAGTTGG; for KIFAP3: Fw CGGGGTTCT
GCTTTGATCCT, Rev AGGACCCTTGCTAATGCACC.
Semiquantitative PCR for PDE5 and PDE11 were per-
formed by using primers and conditions already described
by Aversa A. et al. [31].
Immunofluorescence analysis
For immunofluorescence analysis, 104 cells were seeded
onto glass cover slips in growth medium and maintained for
24 h in serum-free medium. For GLUT4, FLOT1, and
CAV1 cells were stimulated for 30min with tadalafil (0.5 μM),
I (100 nM), sildenafil (1 µM) and 8-br-cGMP (10 µM) in
serum-free medium containing 0.1% BSA. Cells in serum-
free medium with 0.1% BSA and vehicle were used as
control. To evaluate GLUT4 translocation, cells were fixed
with 4% PFA at room temperature and incubated with
blocking buffer containing 1% BSA for 30 min at room
temperature. Ab GLUT4 (1:100) was incubated overnight,
followed by Cy3 conjugated secondary Ab (1:400).
To evaluate GLUT4, FLOT1, and CAV1 localization,
cells were fixed with 4% PFA at room temperature, per-
meabilized with 1% TX-100 for 10 min and incubated with
blocking buffer containing 1% BSA and 1% TX-100 for
30 min at room temperature. Ab GLUT4 FITC-conjugated
(1:40), FLOT1 (1:200) and CAV1 (1:200) were incubated
overnight followed by Cy3 conjugated secondary Ab
(1:400). For method specificity, slides lacking the primary
Abs were processed. DAPI was used to stain nuclei
(1:10000). Images were acquired at 60× magnification.
Slides were examined with Zeiss Z1 microscope and Leica
TCS SP2 (Leica, Milano, Italy). Experiments were per-
formed three times with different cell preparations. For
quantification, the percentage of GLUT4 positive cells was
calculated by counting the number of stained cells over the
total in at least 10 separate fields per slide. Experiments
were performed three times with different cell
preparations.
Protein analysis by western blot
For western blot analysis, Hfsmc, seeded and maintained in
the same conditions as previously reported [32] were sti-
mulated or not for the indicated times with tadalafil (0.5 μM)
or I (100 nM) in serum-free medium containing 0.1% BSA.
Protein concentration measurement was performed with
Bradford Reagent. Protein aliquots (20 μg) were processed,
loaded onto SDS-PAGE and transferred on nitrocellulose
membranes, according to the procedure previously descri-
bed [24, 33]. Thereafter, membranes were incubated with
primary Abs diluted in Tween Tris-buffered saline (1:1000
for p-AKT1/2/3Ser473, p-IRSTyr632, p-mTORSer2441, p-
mTORSer2448, p-GSK3-βSer21/9, AKT, IRS, mTOR, and
GSK3-β, 1:3000 for β-ACTIN), followed by peroxidase-
conjugated secondary IgG (1:10000). Proteins were
revealed by the enhanced chemiluminescence system
(ECL). Image acquisition was performed with Image Quant
Las 4000 software (GE Healthcare) and densitometric
analysis with Quantity One® software (Bio-Rad laboratories
Inc.). Western blot analysis was performed for four/five
independent experiments with different cell preparations.
Bio-plex phosphoprotein assay
Bio-Plex Phosphoprotein Assay was performed as already
described [34]. Briefly, after stimulation, Hfsmc were
washed with ice-cold PBS, harvested and lysed in a
phosphoprotein-lysis-buffer (Bio-Rad Laboratories, Inc.).
After centrifugation (4500 g, 20 min, 4°C), the supernatant
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containing the phosphoprotein was collected and protein
measurement performed. Ribosomal protein S6 kinase beta-
1 phosphorylation (p-P70/S6K) was measured in triplicates
using the Bio-Plex protein array system (Bio-Rad Labora-
tories, Inc.), according to the manufacturer’s protocol. The
system is a multiplexed particle-based flow cytometric
assay that utilizes anti-phosphokinase monoclonal anti-
bodies linked to microspheres incorporating distinct pro-
portions of two fluorescent dyes. Experiments were
performed in triplicate with different cell preparations.
Free fatty acid assays
Intracellular total lipid amount in Hfsmc has been detected
by Sudan B black staining and Abcam Quantification kit
(ab65341) according to manufacturer’s recommendation.
Sudan B black staining
104 Hfsmc were seeded onto glass coverslips in growth
medium and maintained for 24 h in phenol-red and serum-
free medium in presence or in absence of tadalafil 0.5 μM,
sildenafil 1 µM or 8-br-cGMP 10 µM. Cells were fixed with
1% PFA for 15 min at room temperature, were washed in
dH2O and 70% ethanol for 2 min and then stained with
Sudan B Black solution in 70% ethanol for 10 min. Stained
cells were visualized by Nikon Eclipse Ti-S microscope.
Abcam free fatty acid quantification kit
106 Hfsmc were seeded onto glass coverslips in growth
medium and maintained for 24 h in phenol-red and serum-
free medium in presence or in absence of tadalafil 0.5 and 1
μM. Cells extraction and intracellular ffa quantification
were performed according to manufacturer’s recommenda-
tion. Experiments were performed three times with different
cell preparations.
Statistical analysis
The statistical analysis was performed using GraphPad
Prism 5 software (GraphPad Software, Inc., La Jolla,
CA, USA) and SPSS 12.0 software package (SPSS for
Windows 12.0, SPSS Inc., Chicago, IL, USA). The
Kolmogorov–Smirnov test, for normal distribution of the
data, one-way analysis of variance (ANOVA), T-test were
applied. A P value < 0.05 was considered significant and
corrected for comparison using the Dunnett’s or Bonferro-
ni’s post hoc test, where appropriate. Data were expressed
as the mean± standard error (SE).
Results
Tadalafil upregulated I-related gene expression in
Hfsmc
Time-course gene analysis showed that tadalafil (0.5 μM) and
I (100 nM) significantly increased GLUT4- and IRS-1-
expression (Fig. 1a and b, respectively) after 12 h; GLUT4
mRNA is higher with tadalafil (P< 0.05 vs. I). The increase
in PPARγ expression starting from 3 h after treatment with
both drugs was maintained to 12 h (P< 0.05 vs. c and P<
0.05 tadalafil vs. I). KIF1C, HK2, and KIFAP3 mRNA (Fig.
1d–f) was higher vs. c after 3 h (P< 0.05 vs. c); tadalafil
induced HK2 (Fig. 1e) expression greater than I (P< 0.05).
Tadalafil promoted GLUT4 intracellular/membrane re-
localization and trafficking in Hfsmc
Permeabilized Hfsmc, treated (30min) with I (100 nM) or
tadalafil (0.5 µM) (Fig. 2a, panels b and c, respectively)
showed higher specific signal for GLUT4 (green) as compared
to control cells (c), which revealed a weak signal (Fig. 2a,
panel a).
Immunodecoration for CAV1 (red) was similar in con-
trol and in cells treated with I or tadalafil (Fig. 2a, panels
d–f). GLUT4 co-localized in CAV1 positive intracellular
sites, as shown by merged images at higher magnification
(Fig. 2a, panels j–l).
Specific fluorescent signal for FLOT1 (red), almost unde-
tectable in control cells (Fig. 2b, panel d) appeared similarly
intensified after I or tadalafil (Fig. 2b, panels e and f, respec-
tively). GLUT4 fluorescent signal (green) was confirmed to be
stronger after I or tadalafil (Fig. 2b, panels b and c) than in
control cells (Fig. 2b, panel a). Protein stain merging (yellow)
showed GLUT4/FLOT1 cytoplasmatic co-localization after I
or tadalafil (Fig. 2b panel k and l) vs. control (panel j), as
shown in higher magnified pictures. Nuclei are stained with
blue DAPI (Fig. 2a and b, panels g–i).
An intense (red) immunodecoration for GLUT4 was con-
firmed in non permeabilized Hfsmc after 30min tadalafil or I
vs. control (Figure S1, panels a–c); interestingly, GLUT4-
fluorescent signal was undetectable after 30 treatment with
sildenafil (1 µM) or 8-br-cGMP (10 µM), respectively (Figure
S1, panels d, e); nuclei are DAPI blue-stained (panels f–l),
lower panels represent dye merging (m–q).
Diagram below pictures depicts the percentage of
GLUT4-positive stained cells, which are significantly
higher only after tadalafil and I (P< 0.001 vs. control).
Tadalafil activated I-responsive cascade in Hfsmc
The treatment of Hfsmc with tadalafil (0.5 μM) or I (100 nM)
for 10 min significantly increased the phosphorylation of
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mTOR Ser2448 (p-mTORSer2448) and IRS-1 Tyr632 (p-
IRSTyr632) residue, as shown by densitometric analysis of
western blots, expressed as ratio between phospho-protein
and total-protein content (P< 0.05 vs. control, Fig. 3a and
b). Tadalafil failed to activate the phosphorylation of mTOR
Ser2481 (p-mTORSer2481) and Akt1/2/3 Ser473 (p-AKT1/2/
3Ser473) differently from I (P> 0.05 vs. control, Fig. 3c and
d). Representative blots showing phospho-protein and total-
protein for each path analyzed are depicted below histo-
grams. Phosphorylation of P70/S6K protein was
significantly induced only after I (P< 0.05 vs. control), as
shown by the Bio-Plex® suspension array protein analysis
system (Fig. 3e).
Since we have previously demonstrated tadalafil-induced
phosphorylation/inactivation of GSK-3β [17], a pivotal
regulator of I-dependent glucose transport in muscle [35],
we analyzed GSK-3β phosphorylation after 10 min treat-
ment with sildenafil (1 µM) or 8-br-cGMP (10 µM), and
found no modulation on protein activation, at variance with
tadalafil (Figure S2).
Fig. 1 Tadalafil upregulated in Hfsmc GLUT4, IRS-1, PPARγ, KIF1C,
HK2, and KIFAP3 mRNA expression with the same temporal pattern
as I. a–f Tadalafil (0.5 μM) modulated GLUT4, IRS-1, PPARγ, KIF1C,
HK2, and KIFAP3mRNA expression with a similar temporal pattern as
I (100nM). Diagrams in panels a–c show specific mRNAs of GLUT4,
IRS-1, and PPARγ, time-dependently upregulated with higher expres-
sion after 12 h; panels d–f depict KIF1C, HK2, and KIFAP3 mRNA
highest amount induced at 3 h (*P< 0.05 vs. c, $P< 0.05 vs. I). Results
are derived from three experiments with different cell preparations and
expressed as fold increase (mean± SE) vs. c, taken as 1
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Tadalafil induced free fatty acid synthesis in Hfsmc
Intracellular ffa amount significantly increased after tada-
lafil (0.5 µM) as compared with control (P< 0.05, Fig. 4a).
Cells stained with Sudan B Black (Fig. 4b) showed a sig-
nificant increase of Sudan-stained spot number after tada-
lafil vs. control (P< 0.01). The treatment with sildenafil (1
µM) or 8-br-cGMP (10 µM) did not modify intracellular ffa
amount as shown by Sudan B Black staining and intracel-
lular positive-stained spot number (Figure S3, upper and
lower panels);
Hfsmc express PDE5 but not PDE11
Hfsmc cells from upper (UpL) and lower (LwL) limb
showed PDE5 but not PDE11 mRNA expression as com-
pared to LNCaP prostate cancer cells (LNCaP), used as
positive control [36] (Fig. 5).
Discussion
The main finding of the study is that tadalafil controls
GLUT4 membrane re-localization and intracellular traf-
ficking, induces specific residue phosphorylation of IRS-1/
AKT/mTOR complex in association with lipid substrate
regulation, as shown by ffa amount.
The large use of PDE5i for ED treatment in subjects with
diabetic and cardiovascular diseases has led to the devel-
opment of studies in to their extra-sexual effects.
Previous researches showed the association between
PDE5 specific inhibition by sildenafil and glucose home-
ostasis improvement in insulin resistant high fat-fed mice
[37, 38].
Studies in humans documented as well tadalafil-induced
positive metabolic effects in insulin-resistant T2D patients
[39–41], and in ED men without IR, who showed 30%
increase in insulin basal secretion after drug intake [42].
Initially, the principal mechanism describing PDE5i impact
Fig. 2 Tadalafil modulated GLUT4 localization, intracellular trafficking
and co-localization with FLOT1 and CAV1 in Hfsmc. a Immuno-
fluorescence analysis in permeabilized Hfsmc show an intense immuno-
fluorescent specific signal for GLUT4 (green) in presence of I (100 nM,
panel b) or tadalafil (0.5 μM, panel c) vs. respective c (panels a);
immunofluorescent signal for CAV1 (red) was comparable in control and
cells treated with I or tadalafil (panels d–f); blue nuclei are stained with
DAPI (panels g–i); green/red fluorescence merging (panels j–l) showed
intracellular sites of GLUT4/CAV1 co-localization (yellow). b After
treatment with I or tadalafil, similar higher fluorescent signal for GLUT4
(green, panels b and c) and FLOT1 (red, panels e and f) was found vs. c
(panels a and d, respectively); nuclei were stained with DAPI (panels
g–i); merging (panels j–l) showed GLUT4/FLOT1 co-localization (yel-
low). Excerpts represented magnified regions of co-localization from the
original images represented by the outlined area of interest indicated in the
merged panels. Pictures are representative; magnification 60X
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Fig. 3 Effect of tadalafil on activation of insulin-related intracellular
cascade in Hfsmc. a–d Western blot analysis of p-mTORSer2448, p-IRS-
1Tyr632, p-mTOR
Ser2481, and AKTSer473 in Hfsmc treated with I (100 nM)
or tadalafil (0.5 μM)for 10min. Upper panels a–d, show densitometric
analysis and indicate a significant increase of phosphorylation level of
each analyzed path (*P< 0.05 vs. c, $P< 0.05 vs. tadalafil); conversely,
after tadalafil a phosphorylation significantly increased only for
mTORSer2448a and IRS-1Ser473b (*P< 0.05 vs. c; lower panels a–d show
representative western blots; total protein were used as loading controls.
Densitometric analysis was calculated as ratio phosphorylated/total pro-
teins and expressed as fold increase vs. c, taken as 1. e Bio-Plex® sus-
pension array system showed that I (*P< 0.05) but not tadalafil, increased
P70/S6K protein phosphorylation vs. control. Experiments were repeated
three/four times and performed with two different cells preparations
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onto metabolic processes was primarily based on indirect
effect of NO, which plays a pivotal role in mediating I-
induced metabolic processes at muscular level [12, 43–45].
We have previously reported that tadalafil directly tar-
geted Hfsmc with an I-like effect, by activating part of the
energy-dedicated cell machinery [17].
This is the first study to show a similar time-dependent
upregulation of I-targeted gene expression by I and tadalafil,
with higher mRNA induction after 3 h (KIF1c, HK2,
KIFAP3) or 12 h treatment (GLUT4, PPARγ, IRS-1). Data
from protein and intracellular trafficking analysis docu-
mented tadalafil-induced I-like mechanisms involved in
energy regulation within human skeletal muscle cells. The
intense specific signal for GLUT4 as observed in non-
permeabilized Hfsmc after a rapid exposure to tadalafil or I
was virtually undetectable in control cells, when GLUT4 is
likely masked within storage compartments [46]; neither
sildenafil nor cGMP synthetic analog exert any appreciable
effect onto GLUT trafficking, suggesting a specific effect of
tadalafil onto GLUT4 membrane re-localization. Moreover,
tadalafil-induced GLUT4 re-localization in cell sites posi-
tively immune-decorated for CAV1 and FLOT1, as found in
cells after permeabilization, suggests the involvement of
specific platforms for GLUT4 internalization and trafficking,
known as lipid rafts [47]. These sites are cell membrane
protein assemblies which serve as platforms for a correct and
coordinated GLUT4 internalization and trafficking [48–50].
While CAV1 is a “structural” protein [51–53] and similarly
expressed in both control and treated cells, FLOT1 is induced
during GLUT4 trafficking and appears, indeed, positively
modulated in Hfsmc after tadalafil or I vs. control, as shown
by the specific immunodecorated signal. Dysregulation of
this biomolecular protein system in skeletal muscle cells or
adipocytes is linked to diabetic phenotype, IR or T2D
development [49–53]. Furthermore, we found that tadalafil
rapidly phosphorylated the I-responsive intracellular complex
IRS-1/AKT/mTOR. mTOR, downstream effector of IRS-1
[54] associated with AKT activation [52], is characterized by
distinct complexes, mTORC1 and mTORC2; those multi-
protein complexes retain different related effectors and seem
to exert different biological functions activities [55]. While
mTORC1 is sensitive to nutrient/nutrient depletion and
involved mainly in cell growth, cell cycle, and metabolism,
mTORC2 controls mostly cell survival and cytoskeleton re-
arrangement and seems insensitive to nutrient/energy condi-
tions [56]. In particular, AKT phosphorylation onThr308
residue, which we have previously seen after tadalafil treat-
ment [17], is shown to interact with TORC1, whereas AKT
phosphorylation on Ser473 residue seems linked to TORC2
activity [57–59].
Our results document tadalafil-induced activation of
mTOR Ser2448 residue and exclude AKT Ser473 phos-
phorylation and mTOR Ser2481 activation, which mirrors
TORC2 engagement; conversely, tadalafil induced mTOR
Ser2448 residue activation.
TORC1 phosphorylates S6K and 4EBP1 which induces
protein synthesis, cell growth [60] and autophagy inhibi-
tion, as well as simultaneously repressing TORC2 function
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Fig. 4 Effect of tadalafil on intracellular free fatty acids amount in
Hfsmc. a The treatment with tadalafil (0.5 µM, 24 h) increased free
fatty acid production in Hfsmc (*P< 0.05). b Cells after tadalafil (0.5 µM,
24 h) showed significantly higher number of Sudan B Black-stained
spots vs. c (***P< 0.001)
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Fig. 5 Evaluation of PDE11 and PDE5 mRNA expression in Hfsmc
cells. PCR shows that Hfsmc from upper (UpL) and lower (LwL) limb
express PDE5 but not PDE11 mRNA. LNCaP cell line was used as
positive control. β-actin was used as loading control
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[59]. As from our data, S6K seems unaffected by tadalafil.
Previous data similarly reported mTORC1 pathway acti-
vation independently of S6K phosphorylation [60]; this
latter effect is probably due to the involvement of TORC1
differential effectors. The effect of tadalafil onto S6K needs
confirmation in other experimental conditions, i.e., mod-
ifying the time of cell exposition to tadalafil or glucose
concentration (from fully glucose deprivation, to mimic
dietary restriction, or high glucose doses, to mimic dietary
surplus); 4EBP1 phosphorylation needs to be evaluated as
well.
So far, tadalafil in Hfsmc seems to activate selectively, at
least in our experimental conditions, TORC1 path, engaged
in energy regulation. In turn, tadalfil-induced
TORC1 signaling path activation is associated with down-
tream GSK-3β inhibition in Hfsmc, as previously reported
[17]. Of note, GSK3 selective inhibition is known to
improve insulin-resistant skeletal muscle [35] and has been
suggested as a tool for T2D control [61]. Differently from
tadalafil, sildenafil and synthetic cGMP analog failed both
to change GSK-3β status.
TORC1 activation is reported to be linked to an increase
of ffa biosynthesis [62]. TORC1, indeed, regulates posi-
tively the element binding protein 1 (SREBP1) and PPARγ
gene expression [63, 64], two transcription factors engaged
in expression regulation of mRNA encoding proteins
involved in lipid and cholesterol homeostasis [65, 66]. We
found, indeed, a significant upregulation of mRNA specific
for PPARγ 3 and 12 h after tadalafil, similarly to I. After
tadalafil we observed an increase of intracellular ffa amount,
in line with drug-induced rise in ffa release, as previously
shown in Hfsmc supernatants [17].
As we have previously hypothesized, this effect is likely
the result of tadalafil-induced citrate shunt/accumulation
[17], which, in Hfsmc seems to end in ffa production–as
lactate release by these cells has never been observed [17].
It is well known that the ectopic lipid droplets and excess
in lipid accumulation in non-adipose tissue is the main
critical mechanism responsible for skeletal muscle IR
development. However, lipids have been long also recog-
nized as a metabolic fuel source for muscle activity [67, 68].
Indeed, the investigations onto mechanisms underlying
fatty acid content in muscle have been framed in distinct
contexts: fuel metabolic functions and IR-related lipotoxic
effects [69].
While intramyocellular content is predictive of IR/dia-
betes risk, ffa storage as intramuscular triglycerides, con-
versely, seems to be a protective mechanism against IR,
when ffa uptake by muscle is increased due to high lipi-
demic profile (i.e., following lipid-rich diet).
However, intramuscular lipid synthesis rate, rather than
intramuscular concentration, has been supposed to be the
critical factor related to I sensitivity [70, 71].
This observation took first place from a phenomenon
termed “athlete’s paradox” and observed in endurance-
trained athletes, who display intramyocellular higher
synthesis rate and lipid content coupled to I sensitivity
enhancement vs. sedentary subjects [70]. Studies performed
with isotopic tracers confirmed that intramuscular lipid is
utilized as fuel source by muscle itself during exercise [72].
So far, the athlete’s paradox might represent the con-
vergence of the distinct research contexts, discriminating
healthy-related or disease-related function of intramyocel-
lular lipids, based on the novo synthesis at muscular cell
level.
In this view, we could contextualize tadalafil-induced ffa
synthesis in human skeletal muscle cells as a mechanism
potentially related to I sensitivity; this effect seems speci-
fically tadalafil-related, as suggested by the lack of any
change in ffa intracellular amount after sildenafil or 8-br-
cGMP.
Understanding the significance of intramuscular lipid
metabolism/production as fuel in human health is complex.
Many variables should be considered when facing this
topic, from lipid/ffa types, fasting or feeding conditions,
sedentary or active status [73]. Our experiments were all
performed in starving conditions to avoid any possible
interference by other nutrients present, i.e., in serum-
supplemented growth medium and ensure that the effects
observed were evoked by to tadalafil; as previously
addressed, further investigations modifying experimental
conditions (glucose concentration, drug doses, time of
treatment) are mandatory.
Based on the experimental evidence so far collected in
Hfsmc, we speculate that tadalafil exerts its specific effect
directly sensitizing I-responsive intracellular paths with a
mechanism independent of cGMP, whose level, however, is
increased after cell exposure to the drug, as previously
reported [17]. In addition, neither 8-br-cGMP nor sildenafil,
known to stabilize intracellular cGMP levels, targeted ske-
letal muscle metabolic trafficking and paths: in line with this
observation, it has been shown that sildenafil failed to
activate downstream I-signaling in muscle extracts of high-
fat fed mice, albeit controlling muscle glucose homeostasis
[37].
Glucose trafficking in skeletal muscle cells, either
contracting or non-contratting, might also depend on NO
[74, 75], independently from I-responsive paths involve-
ment [76]. Since NO is described to regulate skeletal muscle
glucose homeostasis trough cGMP, we speculate that
tadalafil in Hfsmc, working independently of cGMP, may
not involve muscular NO. However, those mechanisms-
NO-driven or I-driven might occur simultaneously and
independently [76]. Our future investigations, aimed to
further clarify the fine-tuned biomolecular mechanisms
underlying tadalafil action, include studies on NO possible
Endocrine
direct effects onto muscular glucose homeostasis. In con-
clusion, in human skeletal muscle cells tadalafil likely
favors energy storage by modulating lipid homeostasis via
IRS-1-mediated mechanisms, involving direct activation of
I-targeted genes and proteins. Since we have shown the
presence of PDE5 but not PDE11 in Hfsmc, in line with
some authors [77], the effects observed are due to tadalafil-
mediated PDE5 inhibition, albeit the drug is known to target
PDE11 as well [78]. Those data, while providing some
biomolecular evidences for an I-like effect of tadalafil in
human skeletal muscle cells, explain, in part, tadalafil-
induced favorable control of human metabolism shown by
clinical studies and open to novel therapeutic application for
PDE5i.
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